z-logo
open-access-imgOpen Access
Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against Flaviviruses
Author(s) -
Jinhong Chang,
Lijuan Wang,
Dongling Ma,
Xiaowang Qu,
Haitao Guo,
Xiaodong Xu,
Peter M. Mason,
Nigel Bourne,
Robert M. Moriarty,
Baohua Gu,
JuTao Guo,
Timothy M. Block
Publication year - 2009
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01457-08
Subject(s) - dengue virus , virus , dengue fever , in vitro , cytotoxicity , flaviviridae , biology , biochemistry , vero cell , endoplasmic reticulum , virology , chemistry , viral disease
Imino sugars, such asN -butyl-deoxynojirimycin andN -nonyl-deoxynojirimycin (NNDNJ), are glucose analogues that selectively inhibit cellular α-glucosidase I and II in the endoplasmic reticulum and exhibit antiviral activities against many types of enveloped viruses. Although these molecules have broad-spectrum antiviral activity, their development has been limited by a lack of efficacy and/or selectivity. We have previously reported that a DNJ derivative with a hydroxylated cyclohexyl side chain, called OSL-95II, has an antiviral efficacy similar to that of NNDNJ but significantly less toxicity. Building upon this observation, a family of imino sugar derivatives containing an oxygenated side chain and terminally restricted ring structures were synthesized and shown to have low cytotoxicity and superior antiviral activity against members of theFlaviviridae family, including bovine viral diarrhea virus, dengue virus (DENV), and West Nile virus. Of particular interest is that several of these novel imino sugar derivatives, such as PBDNJ0801, PBDNJ0803, and PBDNJ0804, potently inhibit DENV infection in vitro, with 90% effective concentration values at submicromolar concentrations and selectivity indices greater than 800. Therefore, these compounds represent the best in their class and may offer realistic candidates for the development of antiviral therapeutics against human DENV infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom